Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke : A Post Hoc Analysis of the EXTEND-IA TNK Trials
© 2023 American Academy of Neurology..
BACKGROUND AND OBJECTIVES: The safety and efficacy of tenecteplase (TNK) in patients with tandem lesion (TL) stroke is unknown. We performed a comparative analysis of TNK and alteplase in patients with TLs.
METHODS: We first compared the treatment effect of TNK and alteplase in patients with TLs using individual patient data from the EXTEND-IA TNK trials. We evaluated intracranial reperfusion at initial angiographic assessment and 90-day modified Rankin scale (mRS) with ordinal logistic and Firth regression models. Because 2 key outcomes, mortality and symptomatic intracranial hemorrhage (sICH), were few in number among those who received alteplase in the EXTEND-IA TNK trials, we generated pooled estimates for these outcomes by supplementing trial data with estimates of incidence obtained through a meta-analysis of studies identified in a systematic review. We then calculated unadjusted risk differences to compare the pooled estimates for those receiving alteplase with the incidence observed in the trial among those receiving TNK.
RESULTS: Seventy-one of 483 patients (15%) in the EXTEND-IA TNK trials possessed a TL. In patients with TLs, intracranial reperfusion was observed in 11/56 (20%) of TNK-treated patients vs 1/15 (7%) alteplase-treated patients (adjusted odds ratio 2.19; 95% CI 0.28-17.29). No significant difference in 90-day mRS was observed (adjusted common odds ratio 1.48; 95% CI 0.44-5.00). A pooled study-level proportion of alteplase-associated mortality and sICH was 0.14 (95% CI 0.08-0.21) and 0.09 (95% CI 0.04-0.16), respectively. Compared with a mortality rate of 0.09 (95% CI 0.03-0.20) and an sICH rate of 0.07 (95% CI 0.02-0.17) in TNK-treated patients, no significant difference was observed.
DISCUSSION: Functional outcomes, mortality, and sICH did not significantly differ between patients with TLs treated with TNK and those treated with alteplase.
CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that TNK is associated with similar rates of intracranial reperfusion, functional outcome, mortality, and sICH compared with alteplase in patients with acute stroke due to TLs. However, the CIs do not rule out clinically important differences. TRIAL REGISTRATION INFORMATION: clinicaltrials.gov/ct2/show/NCT02388061; clinicaltrials.gov/ct2/show/NCT03340493.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:100 |
|---|---|
| Enthalten in: |
Neurology - 100(2023), 18 vom: 02. Mai, Seite e1900-e1911 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yogendrakumar, Vignan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.4.21.68 |
|---|
| Anmerkungen: |
Date Completed 03.05.2023 Date Revised 06.05.2023 published: Print-Electronic ClinicalTrials.gov: NCT02388061, NCT03340493 Citation Status MEDLINE |
|---|
| doi: |
10.1212/WNL.0000000000207138 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353845256 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353845256 | ||
| 003 | DE-627 | ||
| 005 | 20231226060939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1212/WNL.0000000000207138 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353845256 | ||
| 035 | |a (NLM)36878701 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yogendrakumar, Vignan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke |b A Post Hoc Analysis of the EXTEND-IA TNK Trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2023 | ||
| 500 | |a Date Revised 06.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02388061, NCT03340493 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 American Academy of Neurology. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: The safety and efficacy of tenecteplase (TNK) in patients with tandem lesion (TL) stroke is unknown. We performed a comparative analysis of TNK and alteplase in patients with TLs | ||
| 520 | |a METHODS: We first compared the treatment effect of TNK and alteplase in patients with TLs using individual patient data from the EXTEND-IA TNK trials. We evaluated intracranial reperfusion at initial angiographic assessment and 90-day modified Rankin scale (mRS) with ordinal logistic and Firth regression models. Because 2 key outcomes, mortality and symptomatic intracranial hemorrhage (sICH), were few in number among those who received alteplase in the EXTEND-IA TNK trials, we generated pooled estimates for these outcomes by supplementing trial data with estimates of incidence obtained through a meta-analysis of studies identified in a systematic review. We then calculated unadjusted risk differences to compare the pooled estimates for those receiving alteplase with the incidence observed in the trial among those receiving TNK | ||
| 520 | |a RESULTS: Seventy-one of 483 patients (15%) in the EXTEND-IA TNK trials possessed a TL. In patients with TLs, intracranial reperfusion was observed in 11/56 (20%) of TNK-treated patients vs 1/15 (7%) alteplase-treated patients (adjusted odds ratio 2.19; 95% CI 0.28-17.29). No significant difference in 90-day mRS was observed (adjusted common odds ratio 1.48; 95% CI 0.44-5.00). A pooled study-level proportion of alteplase-associated mortality and sICH was 0.14 (95% CI 0.08-0.21) and 0.09 (95% CI 0.04-0.16), respectively. Compared with a mortality rate of 0.09 (95% CI 0.03-0.20) and an sICH rate of 0.07 (95% CI 0.02-0.17) in TNK-treated patients, no significant difference was observed | ||
| 520 | |a DISCUSSION: Functional outcomes, mortality, and sICH did not significantly differ between patients with TLs treated with TNK and those treated with alteplase | ||
| 520 | |a CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that TNK is associated with similar rates of intracranial reperfusion, functional outcome, mortality, and sICH compared with alteplase in patients with acute stroke due to TLs. However, the CIs do not rule out clinically important differences. TRIAL REGISTRATION INFORMATION: clinicaltrials.gov/ct2/show/NCT02388061; clinicaltrials.gov/ct2/show/NCT03340493 | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 650 | 7 | |a Tenecteplase |2 NLM | |
| 650 | 7 | |a WGD229O42W |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Churilov, Leonid |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Kleinig, Timothy J |e verfasserin |4 aut | |
| 700 | 1 | |a Yassi, Nawaf |e verfasserin |4 aut | |
| 700 | 1 | |a Thijs, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Teddy |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Darshan |e verfasserin |4 aut | |
| 700 | 1 | |a Bailey, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Dewey, Helen M |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Philip M C |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Wijeratne, Tissa |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Esperon, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Cloud, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Chandra, Ronil V |e verfasserin |4 aut | |
| 700 | 1 | |a Cordato, Dennis J |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Gagan |e verfasserin |4 aut | |
| 700 | 1 | |a Desmond, Patricia M |e verfasserin |4 aut | |
| 700 | 1 | |a Parsons, Mark W |e verfasserin |4 aut | |
| 700 | 1 | |a Donnan, Geoffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Stephen M |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Bruce C V |e verfasserin |4 aut | |
| 700 | 0 | |a EXTEND-IA TNK Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Dowling, Richard |e investigator |4 oth | |
| 700 | 1 | |a Bush, Steven |e investigator |4 oth | |
| 700 | 1 | |a Scroop, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Simpson, Marion |e investigator |4 oth | |
| 700 | 1 | |a Brooks, Mark |e investigator |4 oth | |
| 700 | 1 | |a Asadi, Hamed |e investigator |4 oth | |
| 700 | 1 | |a Ang, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Miteff, Ferdinand |e investigator |4 oth | |
| 700 | 1 | |a Levi, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Rodrigues, Edrich |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Henry |e investigator |4 oth | |
| 700 | 1 | |a Ng, Felix |e investigator |4 oth | |
| 700 | 1 | |a Alemseged, Fana |e investigator |4 oth | |
| 700 | 1 | |a Salvaris, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Rice, Henry |e investigator |4 oth | |
| 700 | 1 | |a de Villiers, Laetitia |e investigator |4 oth | |
| 700 | 1 | |a Brown, Helen |e investigator |4 oth | |
| 700 | 1 | |a Redmond, Kendal |e investigator |4 oth | |
| 700 | 1 | |a Leggett, David |e investigator |4 oth | |
| 700 | 1 | |a Fink, John |e investigator |4 oth | |
| 700 | 1 | |a Collecutt, Wayne |e investigator |4 oth | |
| 700 | 1 | |a Kraemer, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Muller, Claire |e investigator |4 oth | |
| 700 | 1 | |a Coulthard, Alan |e investigator |4 oth | |
| 700 | 1 | |a Mitchell, Ken |e investigator |4 oth | |
| 700 | 1 | |a Clouston, John |e investigator |4 oth | |
| 700 | 1 | |a Mahady, Kate |e investigator |4 oth | |
| 700 | 1 | |a Field, Deborah |e investigator |4 oth | |
| 700 | 1 | |a O'Brien, Bill |e investigator |4 oth | |
| 700 | 1 | |a Clissold, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Clissold, Anna |e investigator |4 oth | |
| 700 | 1 | |a Bolitho, Leslie |e investigator |4 oth | |
| 700 | 1 | |a Bonavia, Luke |e investigator |4 oth | |
| 700 | 1 | |a Bhattacharya, Arup |e investigator |4 oth | |
| 700 | 1 | |a Wright, Alistair |e investigator |4 oth | |
| 700 | 1 | |a Mamun, Abul |e investigator |4 oth | |
| 700 | 1 | |a O'Rourke, Fintan |e investigator |4 oth | |
| 700 | 1 | |a Worthington, John |e investigator |4 oth | |
| 700 | 1 | |a Wong, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Ma, Henry |e investigator |4 oth | |
| 700 | 1 | |a Phan, Thanh |e investigator |4 oth | |
| 700 | 1 | |a Chong, Winston |e investigator |4 oth | |
| 700 | 1 | |a Slater, Lee-Anne |e investigator |4 oth | |
| 700 | 1 | |a Krause, Martin |e investigator |4 oth | |
| 700 | 1 | |a Harrington, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Faulder, Kenneth |e investigator |4 oth | |
| 700 | 1 | |a Steinfort, Brendan |e investigator |4 oth | |
| 700 | 1 | |a Bladin, Christopher |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology |d 1951 |g 100(2023), 18 vom: 02. Mai, Seite e1900-e1911 |w (DE-627)NLM000034355 |x 1526-632X |7 nnns |
| 773 | 1 | 8 | |g volume:100 |g year:2023 |g number:18 |g day:02 |g month:05 |g pages:e1900-e1911 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1212/WNL.0000000000207138 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 100 |j 2023 |e 18 |b 02 |c 05 |h e1900-e1911 | ||